Log In- MESH
- Blue Cross Blue Shield Insurance Plans
- Gene Expression Profiling
- Graft Rejection
- Heart Transplantation
- Humans
- Monitoring, Physiologic
- Outcome Assessment (Health Care)
- Postoperative Complications
- Technology Assessment, Biomedical
- Transplantation, Homologous
- United States
- United States Food and Drug Administration
Gene expression profiling as a noninvasive method to monitor for cardiac allograft rejection.
Source
Technology Evaluation Center Assessment Program. Executive summary 26:8 2011 Nov pg 1-3MeSH
Blue Cross Blue Shield Insurance PlansGene Expression Profiling
Graft Rejection
Heart Transplantation
Humans
Monitoring, Physiologic
Outcome Assessment (Health Care)
Postoperative Complications
Technology Assessment, Biomedical
Transplantation, Homologous
United States
United States Food and Drug Administration
Pub Type(s)
Journal ArticleLanguage
eng
PubMed ID
22724159